Healthy
Conditions
Brief summary
The primary objective of the study was to estimate the magnitude of the error in the prediction of in vivo bioavailability (AUC0-30,Cmax) by means of in vitro dissolution data applying the methods of IVIVC. The secondary objective of the study was to investigate whether the intake of food 30 minutes prior to drug administration affects the systemic exposure of pramipexole SR C2 or not
Interventions
DRUGPramipexole SR C
DRUGPramipexole SR C2
DRUGPramipexole SR C2A
DRUGPramipexole SR C2B
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects as determined by results of the screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age ≥ 18 and ≤ 50 years * BMI ≥ 18.5 and ≤ 29.9 kg/m2
Exclusion criteria
* Hypersensitivity to pramipexole or to other dopamine agonists * Supine systolic blood pressure lower than 110 mmHg and supine diastolic blood pressure lower than 60 mmHg at screening * Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study * Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study * Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial) * Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * Inability to refrain from smoking on in-house trial days * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood donation (≥ 100 mL within four weeks prior to administration or during the trial) * Any laboratory value outside the clinically accepted reference range * Excessive physical activities within the last week before the trial or during the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC0-30 (area under the concentration time curve of pramipexole in blood plasma over the time interval 0 to 30 h after drug administration) | Up to 30 hours after drug administration |
| Cmax (maximum measured concentration of pramipexole in blood plasma) | Up to 30 hours after drug administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-∞ (area under the concentration-time curve of pramipexole in blood plasma over the time interval from 0 extrapolated to infinity), | Up to 30 hours after drug administration | — |
| tmax (time from dosing to the maximum concentration of pramipexole in blood plasma) | Up to 30 hours after drug administration | — |
| λz (terminal rate constant in blood plasma), | Up to 30 hours after drug administration | — |
| t½ (terminal half-life of pramipexole in blood plasma) | Up to 30 hours after drug administration | — |
| MRTpo (mean residence time of pramipexole in the body after oral administration) | Up to 30 hours after drug administration | — |
| CL/F (apparent clearance of pramipexole in the blood plasma after extravascular administration) | Up to 30 hours after drug administration | — |
| AUC0-10 (area under concentration-time curve of pramipexole in blood plasma over the time interval from 0 to the median tmax in the fasted state) | Up to 30 hours after drug administration | — |
| Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2) | Up to 120 hours after drug administration | — |
| Number of subjects with adverse events | Up to 7 days after last drug administration | — |
| Number of subjects with clinically significant findings in vital signs | Up to 7 days after last drug administration | pulse rate, blood pressure |
| Number of subjects with clinically significant findings in laboratory parameters | Up to 7 days after last drug administration | — |
| Number of subjects with clinically significant findings in physical examination | Up to 7 days after last drug administration | — |
| Vz/F (apparent volume of distribution during the terminal phase (λz) following an extravascular dose) | Up to 30 hours after drug administration | — |
| AUC0-24 (area under concentration-time curve of pramipexole in blood plasma over the time interval from 0 to 24 h after drug administration), | Up to 24 hours after drug administration | — |
Outcome results
None listed